Adjuvant effects of low doses of a nuclease-resistant derivative of polyinosinic acid . polycytidylic acid on antibody responses of monkeys to inactivated Venezuelan equine encephalomyelitis virus vaccine

D G Harrington, C L Crabbs, D E Hilmas, J R Brown, G A Higbee, F E Cole Jr, H B Levy, D G Harrington, C L Crabbs, D E Hilmas, J R Brown, G A Higbee, F E Cole Jr, H B Levy

Abstract

Polyriboinosinic.polyribocytidylic acid [poly(I).poly(C)] stabilized with poly-l-lysine and carboxymethylcellulose [poly(ICLC)] has been previously shown to be a compound with marked adjuvant activity when given in high doses with inactivated Venezuelan equine encephalomyelitis (VEE) virus vaccine. This study investigated the effects of much lower doses of poly(ICLC) on the magnitude and kinetics of the primary and secondary humoral antibody responses of rhesus monkeys to inactivated VEE virus vaccine. Monkeys given a single injection of vaccine developed very low neutralizing antibody titers, whereas those given adjuvant plus vaccine had 30- to 100-fold-higher titers which remained elevated for longer than 6 months. Low doses of poly(ICLC) given with VEE virus vaccine resulted in a profound but transient increase in priming of secondary antibody responses to the antigen. In contrast, the administration of poly-l-lysine and carboxymethylcellulose alone without the poly(I).poly(C) component of the complex had no adjuvant effect on antibody responses of monkeys to VEE virus vaccine. The temporal development of antibody by class (immunoglobulin M-immunoglobulin G) in monkeys given two injections of adjuvant-vaccine was not different from that with vaccine alone. Serial hematological and clinical chemistry determinations on monkeys given single or multiple doses of poly(ICLC) with vaccine were not different from values in monkeys given vaccine alone.

References

    1. Proc Natl Acad Sci U S A. 1967 Sep;58(3):1004-10
    1. Proc Natl Acad Sci U S A. 1969 Aug;63(4):1102-7
    1. Science. 1970 Jan 9;167(3915):205-7
    1. Proc Soc Exp Biol Med. 1970 Feb;133(2):439-44
    1. Science. 1968 Aug 23;161(3843):802-4
    1. Proc Soc Exp Biol Med. 1967 Jul;125(3):741-7
    1. Science. 1967 Aug 18;157(3790):819-21
    1. J Infect Dis. 1976 Jun;133 Suppl:A256-9
    1. Am J Trop Med Hyg. 1977 Nov;26(6 Pt 1):1191-8
    1. Antimicrob Agents Chemother. 1977 Jan;11(1):80-3
    1. J Infect Dis. 1977 Apr;135(4):600-10
    1. J Infect Dis. 1977 Jul;136(1):122-6
    1. J Infect Dis. 1977 Aug;136(2):286-91
    1. Science. 1977 Sep 23;197(4310):1289-90
    1. Vopr Virusol. 1977 May-Jun;(3):339-43
    1. Vopr Virusol. 1977 Jul-Aug;(4):438-41
    1. J Infect Dis. 1975 Oct;132(4):434-9
    1. Am J Vet Res. 1976 Jun;37(6):725-30
    1. Infect Immun. 1976 Jul;14(1):318-9
    1. J Immunol. 1971 May;106(5):1191-200
    1. Science. 1968 Nov 15;162(3855):811-3
    1. Proc Natl Acad Sci U S A. 1968 Sep;61(1):340-6
    1. Proc Soc Exp Biol Med. 1969 Jul;131(3):1002-11
    1. Appl Microbiol. 1970 Nov;20(5):821-4
    1. Cancer Res. 1972 May;32(5):889-92
    1. Proc Soc Exp Biol Med. 1972 Sep;140(4):1178-81
    1. Nat New Biol. 1972 May 31;237(74):154-5
    1. J Reticuloendothel Soc. 1973 Nov;14(5):441-8
    1. Toxicol Appl Pharmacol. 1972 Dec;23(4):579-88
    1. Proc Soc Exp Biol Med. 1973 Jul;143(3):638-43
    1. Appl Microbiol. 1974 Jan;27(1):150-3
    1. Proc Natl Acad Sci U S A. 1969 Feb;62(2):357-61
    1. Infect Immun. 1971 Oct;4(4):425-30
    1. J Infect Dis. 1971 Apr;123(4):426-8

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する